Skip to main content

Fowler Neal Franklin's Form 4 filing

Emergent BioSolutions Inc.EBS · filed Mar 12, 2025

Accession no.
0001367644-25-000060
Filed
Mar 12, 2025
Trade date
Mar 12, 2025
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market sales total $204.1K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Fowler Neal FranklinCIK 0001493692Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 12, 2025Common StockSSaleDisposed−35,000$5.83F1−$204,050101,100Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On March 12, 2025, Mr. Fowler sold an aggregate of 35,000 shares of Emergent BioSolutions Inc. common stock. For reporting purposes, the sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $5.81 to $5.89. The Company maintains a record of the transactions and copies will be provided upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)